Q32 Bio (NASDAQ:QTTB) Stock Rated “Outperform” in New Coverage at Leerink Partners

Posted by Francis Steltz on Oct 15th, 2026

Leerink Partners started coverage on shares of Q32 Bio (NASDAQ:QTTB – Free Report) in a report issued on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $40.00 price target on the stock.

A number of other research firms have also recently issued reports on QTTB. Mizuho upgraded shares of Q32 Bio to a “strong-buy” rating in a report on Monday, September 7th. Weiss Ratings upgraded Q32 Bio from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st. HC Wainwright boosted their price objective on Q32 Bio from $13.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Jefferies Financial Group initiated coverage on Q32 Bio in a research report on Monday, September 28th. They set a “buy” rating and a $29.00 price objective for the company. Finally, Morgan Stanley started coverage on Q32 Bio in a research note on Monday, August 24th. They set an “overweight” rating and a $34.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.17.

View Our Latest Research Report on QTTB

Q32 Bio Trading Down 0.6%

Shares of Q32 Bio stock opened at $8.01 on Monday. The firm has a fifty day simple moving average of $12.08 and a 200-day simple moving average of $10.88. The stock has a market capitalization of $238.46 million, a price-to-earnings ratio of 3.89 and a beta of 0.31. Q32 Bio has a 1-year low of $1.90 and a 1-year high of $23.57.

Q32 Bio (NASDAQ:QTTB – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.02. As a group, research analysts predict that Q32 Bio will post -1.54 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Shelia M. Violette sold 2,798 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $46,334.88. Following the completion of the transaction, the insider directly owned 127,771 shares in the company, valued at $2,115,887.76. This represents a 2.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jodie Morrison sold 9,845 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $163,033.20. Following the completion of the sale, the chief executive officer directly owned 343,259 shares of the company’s stock, valued at approximately $5,684,369.04. This trade represents a 2.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 22,054 shares of company stock valued at $320,397. 34.46% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in QTTB. Renaissance Technologies LLC increased its stake in Q32 Bio by 107.7% during the first quarter. Renaissance Technologies LLC now owns 206,915 shares of the company’s stock valued at $1,328,000 after acquiring an additional 107,315 shares during the period. BlackRock Inc. bought a new stake in shares of Q32 Bio in the 2nd quarter worth approximately $1,510,000. Atlas Venture Life Science Advisors LLC lifted its position in shares of Q32 Bio by 29.9% in the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company’s stock worth $34,616,000 after acquiring an additional 625,000 shares during the period. Carlyle Group Inc. acquired a new stake in shares of Q32 Bio during the 2nd quarter worth approximately $769,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Q32 Bio during the 2nd quarter worth approximately $303,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

About Q32 Bio

(Get Free Report)

Q32 Bio is a clinical-stage biotechnology company focused on developing therapies designed to restore immune homeostasis and address diseases driven by immune dysregulation. The company’s approach targets pathways involved in the transforming growth factor beta superfamily, which plays a role in regulating inflammation, tissue repair and immune responses.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to modulate immune activity through selective targeting of the activin receptor type IIA pathway.